FDA Accepts Bristol Myers Squibb's Iberdomide NDA for Relapsed Multiple Myeloma
Event summary
- FDA accepted Bristol Myers Squibb's NDA for iberdomide (IberDd) in relapsed/refractory multiple myeloma.
- PDUFA target date set for August 17, 2026.
- Application based on MRD negativity data from Phase 3 EXCALIBER-RRMM trial.
- FDA granted Breakthrough Therapy designation for iberdomide.
- Review conducted under FDA's Project Orbis initiative.
The big picture
Bristol Myers Squibb's NDA acceptance for iberdomide underscores the growing importance of MRD as a surrogate endpoint in oncology. The Breakthrough Therapy designation and Project Orbis review highlight the strategic value of novel treatments for relapsed/refractory multiple myeloma, a market with significant unmet needs. The success of iberdomide could validate Bristol Myers Squibb's targeted protein degradation platform, potentially opening new avenues for undruggable cancer targets.
What we're watching
- Regulatory Timeline
- Whether the FDA will meet the August 2026 PDUFA date for iberdomide approval.
- Clinical Efficacy
- How the MRD negativity endpoint translates into long-term progression-free survival benefits.
- Commercial Potential
- The pace at which iberdomide could capture market share in the relapsed/refractory multiple myeloma space.
Related topics